Literature DB >> 12358765

Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease.

D L Taylor1, L T Diemel, M L Cuzner, J M Pocock.   

Abstract

Regulation of microglial reactivity and neurotoxicity is critical for neuroprotection in neurodegenerative diseases. Here we report that microglia possess functional group II metabotropic glutamate receptors, expressing mRNA and receptor protein for mGlu2 and mGlu3, negatively coupled to adenylate cyclase. Two different agonists of these receptors were able to induce a neurotoxic microglial phenotype which was attenuated by a specific antagonist. Chromogranin A, a secretory peptide expressed in amyloid plaques in Alzheimer's disease, activates microglia to a reactive neurotoxic phenotype. Chromogranin A-induced microglial activation and subsequent neurotoxicity may also involve an underlying stimulation of group II metabotropic glutamate receptors since their inhibition reduced chromogranin A-induced microglial reactivity and neurotoxicity. These results show that selective inhibition of microglial group II metabotropic glutamate receptors has a positive impact on neuronal survival, and may prove a therapeutic target in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358765     DOI: 10.1046/j.1471-4159.2002.01062.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  36 in total

1.  Metabotropic glutamate receptor-mediated signaling in neuroglia.

Authors:  David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-11

2.  Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals.

Authors:  Soong Ho Kim; Paul E Fraser; David Westaway; Peter H St George-Hyslop; Michelle E Ehrlich; Sam Gandy
Journal:  J Neurosci       Date:  2010-03-17       Impact factor: 6.167

Review 3.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

4.  Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis.

Authors:  B Teter; T Morihara; G P Lim; T Chu; M R Jones; X Zuo; R M Paul; S A Frautschy; G M Cole
Journal:  Neurobiol Dis       Date:  2019-04-02       Impact factor: 5.996

Review 5.  Let's make microglia great again in neurodegenerative disorders.

Authors:  Marie-Victoire Guillot-Sestier; Terrence Town
Journal:  J Neural Transm (Vienna)       Date:  2017-10-12       Impact factor: 3.575

6.  Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand.

Authors:  Deanna L Taylor; Fleur Jones; Eva S F Chen Seho Kubota; Jennifer M Pocock
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

7.  Putative mGluR4 positive allosteric modulators activate Gi-independent anti-inflammatory mechanisms in microglia.

Authors:  Gelareh Abulwerdi; Bogdan A Stoica; David J Loane; Alan I Faden
Journal:  Neurochem Int       Date:  2020-05-23       Impact factor: 3.921

8.  Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity.

Authors:  Kimberly R Byrnes; Bogdan Stoica; David J Loane; Angela Riccio; Margaret I Davis; Alan I Faden
Journal:  Glia       Date:  2009-04-01       Impact factor: 7.452

9.  Dual effect of CD4+CD25+ regulatory T cells in neurodegeneration: a dialogue with microglia.

Authors:  Jonathan Kipnis; Hila Avidan; Rachel R Caspi; Michal Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-26       Impact factor: 11.205

10.  Evidence group I mGluR drugs modulate the activation profile of lipopolysaccharide-exposed microglia in culture.

Authors:  Mark C Farso; Ross D O'Shea; Philip M Beart
Journal:  Neurochem Res       Date:  2009-05-29       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.